Basic Information
| RNALocate ID: | RLID:11001973 |
| RNA Symbol: | hsa-miR-193a-3p |
| Localization: | Exosome |
RNA Information
| RNA Name: | hsa-miR-193a |
| RNA ID: | miRBase:MIMAT0000459 |
| RNA Category: | miRNA |
| Species: | Homo sapiens |
Localization Information
| PubMed ID: | 28246603 |
| Tissue/Cell Line: | Urine |
| Method: | qRT-PCR |
| Condition: | Primary focal segmental glomerulosclerosis (FSGS)|Minimal change disease |
| Description: | Urinary exosomal microRNA was extracted, and the expression levels of exosomal miR-193a were quantified by real-time PCR. The levels of urinary exosomal miR-193a were significantly higher in children with primary FSGS than those in children with MCD. |
Other Subcellular Localization
| RNALocate ID | Localization | Tissue/Cell line | PubMed ID |
| RLID:01001854 | Cytoplasm | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:01001855 | Nucleus | Breast adenocarcinoma cells (MCF-7)|Cervical adenocarcinoma cells (HeLa) | 24918059 |
| RLID:11001974 | Exosome | B cell line (Raji)|Primary dendritic cells|T cell line (J77) | 21505438 |
| RLID:11001975 | Exosome | Brain tissue | 23382797 |
| RLID:11001976 | Exosome | Plasma | 23663360 |
| RLID:11001977 | Exosome | Human mast cell line (HMC-1) | 24009880 |
| RLID:11001978 | Exosome | Serum | 24683445 |
| RLID:11001979 | Exosome | Colon cancer cell line (LIM1863) | 25330373 |
| RLID:11001980 | Microvesicle | Seminal plasma | 23539611 |
| RLID:11001981 | Microvesicle | Hepatoma cells | 23771658 |
| RLID:11001982 | Microvesicle | Colon cancer cell line (LIM1863) | 25330373 |
| RLID-D:11000102 | Exosome | Breast milk | |
| RLID-D:11000387 | Microvesicle | Colon cancer cell line (LIM1863)|Fibroblasts|Mesenchymal stem cells|Urine |
ncRNA Disease Information
| Resource | RNA Symbol | Disease | Link |
| MNDR | hsa-miR-193a-3p | Multiple sclerosis chronic progressive | MNDR-E-MI-22928 |
| MNDR | hsa-miR-193a-3p | Oral squamous cell carcinoma | MNDR-E-MI-22929 |
| MNDR | hsa-miR-193a-3p | Medulloblastoma | MNDR-E-MI-22930 |
| MNDR | hsa-miR-193a-3p | Small intestinal neuroendocrine tumor | MNDR-E-MI-22931 |
| MNDR | hsa-miR-193a-3p | Ovarian clear cell carcinoma | MNDR-E-MI-22932 |
| MNDR | hsa-miR-193a-3p | Estrogen-receptor positive breast cancer | MNDR-E-MI-22933 |
| MNDR | hsa-miR-193a-3p | Progesterone-receptor positive breast cancer | MNDR-E-MI-22934 |
| MNDR | hsa-miR-193a-3p | Progesterone-receptor negative breast cancer | MNDR-E-MI-22935 |
| MNDR | hsa-miR-193a-3p | Her2-receptor positive breast cancer | MNDR-E-MI-22936 |
| MNDR | hsa-miR-193a-3p | Breast cancer luminal a | MNDR-E-MI-22937 |
| MNDR | hsa-miR-193a-3p | Precursor cell lymphoblastic leukemia-lymphoma | MNDR-E-MI-22938 |
| MNDR | hsa-miR-193a-3p | B cell acute lymphoblastic leukemia | MNDR-E-MI-22939 |
| MNDR | hsa-miR-193a-3p | Neurofibromatosis 1 | MNDR-E-MI-22940 |
| MNDR | hsa-miR-193a-3p | Small intestine cancer | MNDR-E-MI-22941 |
| MNDR | hsa-miR-193a-3p | Prostate cancer | MNDR-E-MI-22942 |
| MNDR | hsa-miR-193a-3p | Gastric cancer | MNDR-E-MI-22943 |
| MNDR | hsa-miR-193a-3p | Alzheimer disease | MNDR-E-MI-22944 |
| MNDR | hsa-miR-193a-3p | Dysautonomia familial | MNDR-E-MI-22945 |
| MNDR | hsa-miR-193a-3p | Polycystic ovary syndrome | MNDR-E-MI-22946 |
| MNDR | hsa-miR-193a-3p | Myotonic dystrophy | MNDR-E-MI-22947 |
| MNDR | hsa-miR-193a-3p | Cardiovascular disease | MNDR-E-MI-22948 |
| MNDR | hsa-miR-193a-3p | Lung cancer | MNDR-E-MI-22949 |
| MNDR | hsa-miR-193a-3p | Parkinson disease | MNDR-E-MI-22950 |
| MNDR | hsa-miR-193a-3p | Basal-like breast cancer | MNDR-E-MI-22951 |
| MNDR | hsa-miR-193a-3p | Thyroid cancer | MNDR-E-MI-22952 |
| MNDR | hsa-miR-193a-3p | Pituitary neoplasms | MNDR-E-MI-22953 |
| MNDR | hsa-miR-193a-3p | Pancreatic cancer | MNDR-E-MI-22954 |
| MNDR | hsa-miR-193a-3p | Nephroblastoma | MNDR-E-MI-22955 |
| MNDR | hsa-miR-193a-3p | Colon cancer | MNDR-E-MI-22956 |
| MNDR | hsa-miR-193a-3p | Ischemic attack transient | MNDR-E-MI-22957 |
| MNDR | hsa-miR-193a-3p | Colon adenocarcinoma | MNDR-E-MI-22958 |
| MNDR | hsa-miR-193a-3p | Multiple sclerosis relapsing-remitting | MNDR-E-MI-22959 |
| MNDR | hsa-miR-193a-3p | Familial ovarian cancer | MNDR-E-MI-22960 |
| MNDR | hsa-miR-193a-3p | Acromegaly | MNDR-E-MI-22961 |
| MNDR | hsa-miR-193a-3p | Prostate adenocarcinoma | MNDR-E-MI-22962 |
| MNDR | hsa-miR-193a-3p | Carcinoma ductal breast | MNDR-E-MI-22963 |
| MNDR | hsa-miR-193a-3p | Invasive ductal carcinoma | MNDR-E-MI-22964 |
| MNDR | hsa-miR-193a-3p | Glioblastoma | MNDR-E-MI-22965 |
| MNDR | hsa-miR-193a-3p | Astrocytoma | MNDR-E-MI-22966 |
| MNDR | hsa-miR-193a-3p | Glioma | MNDR-E-MI-22967 |
| MNDR | hsa-miR-193a-3p | Amyotrophic lateral sclerosis | MNDR-E-MI-22968 |
| MNDR | hsa-miR-193a-3p | Temporal lobe epilepsy | MNDR-E-MI-22969 |
| MNDR | hsa-miR-193a-3p | Uterine cancer | MNDR-E-MI-22970 |
| MNDR | hsa-miR-193a-3p | Cervical adenocarcinoma | MNDR-E-MI-22971 |
| MNDR | hsa-miR-193a-3p | Gastric adenocarcinoma | MNDR-E-MI-22972 |
| MNDR | hsa-miR-193a-3p | Cervical squamous cell carcinoma | MNDR-E-MI-22973 |
| MNDR | hsa-miR-193a-3p | Pituitary adenoma | MNDR-E-MI-22974 |
| MNDR | hsa-miR-193a-3p | Lung squamous cell carcinoma | MNDR-E-MI-22975 |
| MNDR | hsa-miR-193a-3p | Carcinoma lung non-small-cell | MNDR-E-MI-22976 |
| MNDR | hsa-miR-193a-3p | Thyroid carcinoma | MNDR-E-MI-22977 |
| MNDR | hsa-miR-193a-3p | Papillary thyroid carcinoma | MNDR-E-MI-22978 |
| MNDR | hsa-miR-193a-3p | Bladder urothelial carcinoma | MNDR-E-MI-22979 |
| MNDR | hsa-miR-193a-3p | Pancreatic adenocarcinoma | MNDR-E-MI-22980 |
| MNDR | hsa-miR-193a-3p | Myasthenia gravis autoimmune experimental | MNDR-E-MI-22981 |
| MNDR | hsa-miR-193a-3p | Carcinoma renal cell | MNDR-E-MI-22982 |
| MNDR | hsa-miR-193a-3p | Kidney renal papillary cell carcinoma | MNDR-E-MI-22983 |
| MNDR | hsa-miR-193a-3p | Clear cell renal cell carcinoma | MNDR-E-MI-22984 |
| MNDR | hsa-miR-193a-3p | Cholangiocarcinoma | MNDR-E-MI-22985 |
| MNDR | hsa-miR-193a-3p | Esophageal cancer | MNDR-E-MI-22986 |
| MNDR | hsa-miR-193a-3p | Lung small cell carcinoma | MNDR-E-MI-22987 |
| MNDR | hsa-miR-193a-3p | Synovial sarcoma | MNDR-E-MI-22988 |
| MNDR | hsa-miR-193a-3p | T acute lymphoblastic leukemia | MNDR-E-MI-22989 |
| MNDR | hsa-miR-193a-3p | Acute t cell leukemia | MNDR-E-MI-22990 |
| MNDR | hsa-miR-193a-3p | Growth hormone-secreting pituitary adenoma | MNDR-E-MI-22991 |
| MNDR | hsa-miR-193a-3p | Breast invasive carcinoma | MNDR-E-MI-22992 |
| MNDR | hsa-miR-193a-3p | Hepatocellular carcinoma | MNDR-E-MI-22993 |
| MNDR | hsa-miR-193a-3p | Familiar ovarian carcinoma | MNDR-E-MI-22994 |
| MNDR | hsa-miR-193a-3p | Barrett's adenocarcinoma | MNDR-E-MI-22995 |
| MNDR | hsa-miR-193a-3p | Hodgkin lymphoma | MNDR-E-MI-22996 |
| MNDR | hsa-miR-193a-3p | Ulcerative colitis | MNDR-E-MI-22997 |
| MNDR | hsa-miR-193a-3p | Burkitt lymphoma | MNDR-E-MI-22998 |
| MNDR | hsa-miR-193a-3p | Tonsil cancer | MNDR-E-MI-22999 |
| MNDR | hsa-miR-193a-3p | Degenerative disc disease | MNDR-E-MI-23000 |
| MNDR | hsa-miR-193a-3p | Acute myelocytic leukemia | MNDR-E-MI-23001 |
| MNDR | hsa-miR-193a-3p | Colorectal cancer | MNDR-E-MI-23002 |
| MNDR | hsa-miR-193a-3p | Nasopharynx carcinoma | MNDR-E-MI-23003 |
| MNDR | hsa-miR-193a-3p | Acute lymphocytic leukemia | MNDR-E-MI-23004 |
| MNDR | hsa-miR-193a-3p | Esophageal squamous cell carcinoma | MNDR-E-MI-23005 |
| MNDR | hsa-miR-193a-3p | Ependymoma | MNDR-E-MI-23006 |
| MNDR | hsa-miR-193a-3p | Inflammation | MNDR-E-MI-23007 |
| MNDR | hsa-miR-193a-3p | Nasopharyngeal cancer | MNDR-E-MI-23008 |
| MNDR | hsa-miR-193a-3p | Pseudorabies | MNDR-E-MI-23009 |
| MNDR | hsa-miR-193a-3p | Barrett's carcinogenesis | MNDR-E-MI-23010 |
| MNDR | hsa-miR-193a-3p | Solid-pseudopapillary neoplasm of pancreas | MNDR-E-MI-23011 |
RNA Interaction Information
| Resource | RNA Symbol | Species | Link | RNALocate ID |
| RNAInter | CASC2 | Homo sapiens | RR00277759 |
TOP